Skip to content
DataLookout
Menu

PANDORANCT07356232

Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease

StatusEnrolling by Invitation
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 4 → 7 locations
  2. Minor Study sites: 5 to 6
    • Start date changed from estimate of Nov 2026 to Nov 3, 2026
  3. Minor Study sites: 4 to 5
  4. Notable Enrolling by invitation only Show 4 more changesShow less
    • Lead sponsor: University of Pennsylvania to James Lewis
    • Start date: Sep 2026 to Nov 2026
    • Eligibility criteria expanded, about 30 words
    • Trial sites expanded: 1 → 4 locations
  5. Minor Start date: Aug 2026 to Sep 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Apr 2026 to Aug 2026v3
  2. Notable Eligibility criteria expanded, about 40 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of steroid-free remission following 8 weeks of pharmacologic therapy
Timeframe: From start of pharmacologic therapy to 8 weeks.

Arms and interventions

Partial enteral nutritionExperimental

Participants will consume Kate Farms Peptide 1.5 for 60% of their calories for 8 weeks

No partial enteral nutritionNo intervention

Dietary supplements: Partial enteral nutrition - orally consumed formula

Sites

7 sites in 1 country